PDL BioPharma Inc (NASDAQ:PDLI)
| 8.22 Data as of May 17 |  +0.04 / +0.49%Today’s Change | 6.16 Today|||52-Week Range 8.43 | +16.76% Year-to-Date |
Latest PDLI News | Press Releases
| PDL BioPharma Misses Earnings Ests - Analyst Blog May 13 / Zacks.com |
Today’s Trading
| Previous close | 8.18 |
| Today’s open | 8.23 |
| Day’s range | -- - -- |
| Volume | 1,301,816 |
| Average volume (3 months) | 1,776,528 |
| Market cap | $1.2B |
| Dividend yield | 7.30% |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | +26.09% |
| Earnings growth (this year) | +13.23% |
| Earnings growth (next 5 years) | +17.00% |
| Revenue growth (last year) | +3.45% |
| P/E ratio | 5.2 |
| Price/Sales | 2.63 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ACADACADIA Pharmaceutica... | +0.26 | +2.00% |
| TSROTESARO Inc | +0.03 | +0.08% |
| SRPTSarepta Therapeutics... | +1.40 | +3.94% |
| INFIInfinity Pharmaceuti... | +0.59 | +2.43% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Next reporting date | July 31, 2013 |
| EPS forecast (this quarter) | $0.54 |
| Annual revenue (last year) | $374.5M |
| Annual profit (last year) | $211.7M |
| Net profit margin | 56.52% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, CEO, CFO, Director & CAO John Peter McLaughlin |
Secretary, Vice President & General Counsel Christopher Lewis Stone |
Corporate headquarters Incline Village, Nevada |
Forecasts
